Inhibitec Antibodies, S.L. Cantabrian biotechnology company has developed a monoclonal antibody for a new therapeutic target

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.

A significant number of psoriatic patients with severe disease do not respond to existing therapies. A key molecule involved its pathogenic is BAMBI and its inhibition with our specific mAbs (BI0137) prevents skins and articular lesions in preclinical experimental models of psoriasis.

IMG-20190522-WA0042 IMG-20190523-WA0020 IMG-20190523-WA0064